产品名称：	二氧化碳专用净化装置 2020年版《中华人民共和国药典》
产品型号：	二氧化碳专用净化装置
品牌：	1941
产品数量：
产品单价：	面议
日期:	2023-06-12

二氧化碳专用净化装置 2020年版《中华人民共和国药典》的详细资料

2020年版《中华人民共和国药典》
2020年版《中华人民共和国药典》 详细信息：

名称：药典二氧化碳（CO2）净化装置

型号：HHO-III Purification device

应用：2020版及2015版中国药典二氧化碳中碳氢化合物测定  气相色谱法

2020年版《中华人民共和国药典》（以下简称《中国药典》）已由国家药品监督管理局 国家卫生健康委2020年第78号公告发布，自2020年12月30日起实施。现就实施本版《中国药典》有关事宜公告如下：

一、根据《药品管理法》的规定，药品应当符合国家药品标准。《中国药典》是国家药品标准的重要组成部分，是药品研制、生产（进口）、经营、使用和监督管理等相关单位均应遵循的法定技术标准。

二、《中国药典》主要由凡例、品种正文和通用技术要求构成。自实施之日起，所有生产上市药品应当符合本版《中国药典》相关技术要求。

三、自实施之日起，凡原收载于历版药典、局（部）颁标准的品种，本版《中国药典》收载的，相应历版药典、局（部）颁标准同时废止；本版《中国药典》未收载的，仍执行相应历版药典、局（部）颁标准，但应符合本版《中国药典》的相关通用技术要求，经上市后评价撤销或注销的品种，相应历版药典、局（部）颁标准废止。

本版《中国药典》品种正文未收载的制剂规格、中药的制法，其质量标准按本版《中国药典》同品种相关要求执行，规格项、制法项分别按原批准证明文件执行。

四、药品注册标准中收载检验项目多于或者异于药典规定的，或者质量指标严于药典要求的，应在执行药典要求的基础上，同时执行注册标准的相应项目和指标。

药品注册标准收载检验项目少于药典规定或质量指标低于药典要求的，应执行药典规定。

浩瀚色谱（山东）应用技术开发有限公司以振兴民族企业为己任，根据2020中国药典二氧化碳中规定的要求：碳氢化合物的含量不大于0.0020%的指标要求，升级改造了HHO-III Purification device净化装置，并命名为2021年NEW款，此款设备更加符合2020版药典，净化效果好，定量准确。

浩瀚色谱，提供详细的操作方法，提供安装图纸。

2020年版《中华人民共和国药典》 测试谱图：


The 2020 edition of the Pharmacopoeia of the People's Republic of China
The 2020 edition of "The Pharmacopoeia of the People's Republic of China" Details:

Name: Pharmacopoeia carbon dioxide (CO2) purification device

Model: HHO-III Purification device

Application: 2020 and 2015 Chinese Pharmacopoeia Determination of Hydrocarbons in Carbon Dioxide Gas Chromatography


The 2020 edition of the "Pharmacopoeia of the People's Republic of China" (hereinafter referred to as the "Chinese Pharmacopoeia") has been issued by the National Medical Products Administration and National Health Commission Announcement No. 78, 2020, and will be implemented on December 30, 2020. The relevant matters concerning the implementation of this edition of the Chinese Pharmacopoeia are hereby announced as follows:

1. According to the provisions of the "Drug Administration Law", drugs should comply with national drug standards. The "Chinese Pharmacopoeia" is an important part of the national drug standards, and is a legal technical standard that should be followed by relevant units such as drug research and development, production (import), operation, use, supervision and management.

2. The "Chinese Pharmacopoeia" mainly consists of legends, variety texts and general technical requirements. From the date of implementation, all drugs produced and marketed shall meet the relevant technical requirements of this edition of the Chinese Pharmacopoeia.

3. From the date of implementation, all varieties that were originally included in the pharmacopoeias of the calendar and the standards issued by the bureaus (ministries), and those included in this edition of the Chinese Pharmacopoeia, the corresponding pharmacopoeias and the standards issued by the bureaus (ministers) shall be abolished simultaneously; If this edition of the "Chinese Pharmacopoeia" is not included, the corresponding historical editions of the pharmacopoeia and bureau (ministerial) standards shall still be implemented, but should comply with the relevant general technical requirements of this edition of the "Chinese Pharmacopoeia". Corresponding historical editions of the pharmacopoeia, bureau (minister) issued standards are abolished.

The quality standards of preparation specifications and preparation methods of traditional Chinese medicines that are not included in the text of this edition of the Chinese Pharmacopoeia shall be implemented in accordance with the relevant requirements of the same variety in this edition of the Chinese Pharmacopoeia, and specifications and preparation items shall be implemented in accordance with the original approval documents.

4. If the drug registration standard contains more inspection items than or different from the pharmacopoeia, or the quality index is stricter than the pharmacopoeia requirements, the corresponding items and indicators of the registration standard shall be implemented on the basis of the pharmacopoeia requirements.

If the inspection items included in the drug registration standards are less than the pharmacopoeia regulations or the quality index is lower than the pharmacopoeia requirements, the pharmacopoeia regulations shall be implemented.





Haohan Chromatography (Shandong) Applied Technology Development Co., Ltd. takes the revitalization of national enterprises as its mission. According to the requirements stipulated in the 2020 Chinese Pharmacopoeia for carbon dioxide: the content of hydrocarbons is not more than 0.0020%, the HHO-III Purification device has been upgraded and transformed. , And named the 2021 NEW model, this device is more in line with the 2020 version of the Pharmacopoeia, with good purification effect, accurate and reliable quantification.

Haohan Chromatography provides detailed operation methods and installation drawings.


The test spectrum of the 2020 edition of "The Pharmacopoeia of People's Republic of China"